Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human TGFBR1 Antibodies:
anti-Mouse (Murine) TGFBR1 Antibodies:
anti-Rat (Rattus) TGFBR1 Antibodies:
Go to our pre-filtered search.
Human Polyclonal TGFBR1 Primary Antibody for IF (p), IHC (p) - ABIN671256
Xie, Chen, Miao, Tang, Fu: Regulation of cellular behaviors of fibroblasts related to wound healing by sol-gel derived bioactive glass particles. in Journal of biomedical materials research. Part A 2016
Show all 3 Pubmed References
Human Polyclonal TGFBR1 Primary Antibody for IHC (p), WB - ABIN392279
Miles, Tung, Aguiar, Kurtoglu, Sikes: Increased TGF-?1-mediated suppression of growth and motility in castrate-resistant prostate cancer cells is consistent with Smad2/3 signaling. in The Prostate 2012
Show all 2 Pubmed References
Human Polyclonal TGFBR1 Primary Antibody for IF, WB - ABIN317892
Yu, Hu, Yang, Takemori, Li, Zheng, Hong, Liao, Wen: Salt-inducible kinase 1 is involved in high glucose-induced mesangial cell proliferation mediated by the ALK5 signaling pathway. in International journal of molecular medicine 2013
Human Polyclonal TGFBR1 Primary Antibody for ELISA, WB - ABIN563176
Matsunobu, Torigoe, Ishikawa, de Vega, Kulkarni, Iwamoto, Yamada: Critical roles of the TGF-beta type I receptor ALK5 in perichondrial formation and function, cartilage integrity, and osteoblast differentiation during growth plate development. in Developmental biology 2009
Mouse (Murine) Monoclonal TGFBR1 Primary Antibody for FACS - ABIN4896300
Bodogai, Moritoh, Lee-Chang, Hollander, Sherman-Baust, Wersto, Araki, Miyoshi, Yang, Trinchieri, Biragyn: Immunosuppressive and Prometastatic Functions of Myeloid-Derived Suppressive Cells Rely upon Education from Tumor-Associated B Cells. in Cancer research 2015
TGFBR1/2 genetic variants (in particular when evaluated as a burden by score) might play a role in modulating the severity of cardiovascular manifestation in Marfan syndrome.
Inhibition of each TGFbeta (show TGFB1 Antibodies) receptor-I, glucocorticoid receptor (show NR3C1 Antibodies) or JNK (show MAPK8 Antibodies) signaling partially reversed the dexamethasone-mediated effects, suggesting a complex signaling network. These data reveal that dexamethasone mediates progression by membrane effects and binding to glucocorticoid receptor (show NR3C1 Antibodies)
DZNep induced miR (show MLXIP Antibodies)-202-5p to target both TGFbeta (show TGFB1 Antibodies) receptors, TGFBR1 and TGFBR2 (show TGFBR2 Antibodies)...transfection of anti-miRNAs against miR (show MLXIP Antibodies)-202-5p resulted in increased TGFBR1 and TGFBR2 (show TGFBR2 Antibodies) protein expressions and induced EMT (show ITK Antibodies) characteristics in these cells. In stellate pancreatic cells, miR (show MLXIP Antibodies)-202 overexpression slowed growth as well as reduced stromal extracellular membrane matrix protein expression
Findings provide evidence that TGFBR-1 expression is regulated by SLC35F2 (show SLC35F2 Antibodies) which exerts its oncogenic effect on papillary thyroid carcinoma progression through activation of TGFBR-1 and ASK-1 (show MAP3K5 Antibodies).
miR (show MLXIP Antibodies)-130a-3p might play a critical role in negatively regulating hepatic stellate cell activation and proliferation in the progression of nonalcoholic fibrosing steatohepatitis by directly targeting TGFBR1 and TGFBR2 (show TGFBR2 Antibodies) via the TGF-beta (show TGFB1 Antibodies)/SMAD (show SMAD1 Antibodies) signaling pathway.
TGFbetaR1 signaling was involved in 14-3-3zeta (show YWHAZ Antibodies)-mediated cell proliferation and metastasis of lung squamous cell carcinoma cells.
Mutational activation of BRAF (show BRAF Antibodies) confers sensitivity to TGFBR1 inhibitors in human melanoma cells.
Loeys-Dietz syndrome patients with confirmed mutations in TGFBR1 or TGFBR2 (show TGFBR2 Antibodies) had an increased prevalence of inflammatory bowel disease
ALK5 is an important mediator of HTFs fibrosis. ALK5 is a potential therapeutic target to suppress scar formation after filtration surgery.
PAR2 (show F2RL1 Antibodies) is crucial for TGF-beta1 (show TGFB1 Antibodies)-induced cell motility by its ability to sustain expression of ALK5. Therapeutically targeting PAR2 (show F2RL1 Antibodies) may thus be a promising approach in preventing TGF-beta (show TGFB1 Antibodies)-dependent driven metastatic dissemination in PDAC and possibly other stroma-rich tumour types.
The results indicate that the TGFBR1 gene polymorphism (SNP64) is significantly associated with growth rates including average daily gains between birth and 56 kg, between 5.5 and 56 kg, between 35 and 56 kg.
Report temporal regulation of TGFBR1 mRNA expression in the oocyte, granulosa and theca cells of developing preovulatory follicles in the pig.
TGFbeta (show TGFB1 Antibodies) is abundant in boar seminal plasma, thus TGFbeta (show TGFB1 Antibodies) may be a male-female signalling agent involved in immune changes in the female reproductive tract elicited by seminal fluid.
Porcine transforming growth factor beta receptor 1 has many polymorphisms, including two nonsynonymous substitutions in exons 1 and 7 and novel alternative splicing in exon 3.
isolation and molecular characterization; the full-length TGFBR1 cDNA 1813 bp contains an open reading frame (ORF) of 1512 bp encoding a TGFBR1 protein of 503 amino acids with a calculated molecular weight of 56.4 kDa.
Results show that ALK5 and ALK1 (show ACVRL1 Antibodies) play antagonistic roles in TGF-beta (show TGFB1 Antibodies)-induced podosome formation in aortic endothelial cells.
This study showed that ubiquitinated ALK5 and phosphorylated heat shock protein 27 (show HSP27 Antibodies) specifically accumulate in the cytoskeleton fraction, and ALK1 (show ACVRL1 Antibodies) and ALK5 interact with heat shock protein 90 (show HSP90 Antibodies).
GM-CSF (show CSF2 Antibodies) induced airway smooth muscle cells to increase expression of transforming growth factor (TGF)-beta (show TGFB1 Antibodies) receptors type I, II, and III, but had no detectable effect on the release of TGF-beta1 (show TGFB1 Antibodies) by the same ASMC; corticosteroids were inhibitory
ALK5 and Smad4 (show SMAD4 Antibodies) have roles in TGF-beta1 (show TGFB1 Antibodies)-induced pulmonary endothelial permeability
These results indicate that high plasma cholesterol levels may contribute to the pathogenesis of certain diseases (e.g., atherosclerosis) by suppressing TGF-beta (show TGFB1 Antibodies) responsiveness.
Transforming growth factor-beta1 protects against pulmonary artery endothelial cell apoptosis via ALK5.
ALK1 (show ACVRL1 Antibodies) and ALK5 are both essential for correct regulation of VEGF (show VEGFA Antibodies), and that disruption of either pathway leads to disease.
TGF-beta1 (show TGFB1 Antibodies) downregulates caveolin-1 (show CAV1 Antibodies) of cultured endothelial cells, involving ALK-5 receptor subtype
Postnatal cartilage-specific deletion of Alk5 induced an OA-like phenotype with degradation of articular cartilage, synovial hyperplasia, osteophyte formation, subchondral sclerosis, as well as enhanced chondrocyte apoptosis, overproduction of catabolic factors, and decreased expressions of anabolic factors in chondrocytes. In addition, the expressions of PRG4 mRNA and protein were decreased in Alk5 conditional KO mice.
Loss of ALK5 is associated with germinal matrix hemorrhage-intraventricular hemorrhage.
this study shows that tissue-specific differentiation of colonic macrophages requires TGFbeta (show TGFB1 Antibodies) receptor-mediated signaling
Taken together, these results indicate that eIF6 (show EIF6 Antibodies) may be involved in external mechanical force-mediated murine dermal fibroblast function at least partly through the TGF-beta1 (show TGFB1 Antibodies)/TGFBR1/TGFBR2 (show TGFBR2 Antibodies) pathway.
expression induced by IL-6 (show IL6 Antibodies) in keratinocytes
Loss of smooth muscle cell-Tgfbr1 triggers multiple deleterious pathways, including abnormal TGFBR2 (show TGFBR2 Antibodies), ERK (show EPHB2 Antibodies), and AngII/AT1R (show AGTRAP Antibodies) signals that disrupt aortic wall homeostasis to cause aortic aneurysm formation
Deletion of smooth muscle cell-specific Tgfbr1 inhibits arterial neointimal hyperplasia in short term, but promotes an undesired vascular phenotype for injured arteries.
TGFbetaR1 signalling is needed for development of CD103 (show ITGAE Antibodies)(+)CD11b (show ITGAM Antibodies)(+) intestinal DCs from CD103 (show ITGAE Antibodies)(-)CD11b (show ITGAM Antibodies)(+) cells and that they contribute to the generation of Th17 and regulatory T cells.
Overactivation of TGFBR1 drives gonadal tumor development. The TGFBR1 constitutively active mouse model phenocopies a number of morphological, hormonal, and molecular features of human granulosa cell tumors and are potentially valuable for preclinical testing of targeted therapies to treat granulosa cell tumors, a class of poorly defined ovarian malignancies.
The protein encoded by this gene forms a heteromeric complex with type II TGF-beta receptors when bound to TGF-beta, transducing the TGF-beta signal from the cell surface to the cytoplasm. The encoded protein is a serine/threonine protein kinase. Mutations in this gene have been associated with Loeys-Dietz aortic aneurysm syndrome (LDAS). Multiple transcript variants encoding different isoforms have been found for this gene.
TGF-beta receptor type I
, TGF-beta receptor type-1
, TGF-beta type I receptor
, activin A receptor type II-like kinase, 53kD
, activin A receptor type II-like kinase, 53kDa
, activin A receptor type II-like protein kinase of 53kD
, activin receptor-like kinase 5
, serine/threonine-protein kinase receptor R4
, transforming growth factor beta receptor I
, transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53kD)
, transforming growth factor-beta receptor type I
, transforming growth factor, beta receptor 1 (activin A receptor type II-like kinase, 53kDa)
, transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53kDa)
, transforming growth factor beta type I receptor
, transforming growth factor, beta receptor 1
, transforming growth factor beta receptor 1
, activin A receptor type II-like kinase
, transforming growth factor beta receptor type I
, transforming growth factor beta, receptor 1
, type I serine/threonine kinase receptor
, TGF-beta receptor type-1-like
, transforming growth factor, beta receptor I